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Abstract
Background: Activity of secreted phospholipase A (sPLA2) has been implicated in a wide range
of cellular responses. However, little is known about the function of human parvovirus B19-VP1
unique region (VP1u) with sPLA2 activity on macrophage.
Methods: To investigate the roles of B19-VP1u in response to macrophage, phospholipase A2
activity, cell migration assay, phagocytosis activity, metalloproteinase assay, RT-PCR and
immunoblotting were performed.
Results: In the present study, we report that migration, phagocytosis, IL-6, IL-1 mRNA, and
MMP9 activity are significantly increased in RAW264.7 cells by B19-VP1u protein with sPLA2
activity, but not by B19-VP1uD175A protein that is mutated and lacks sPLA2 activity. Additionally,
significant increases of phosphorylated ERK1/2 and JNK proteins were detected in macrophages
that were treated with B19-VP1u protein, but not when they were treated with B19-VP1uD175A
protein.
Conclusion: Taken together, our experimental results suggest that B19-VP1u with sPLA2 activity
affects production of IL-6, IL-1 mRNA, and MMP9 activity, possibly through the involvement of
ERK1/2 and JNK signaling pathways. These findings could provide clues in understanding the role
of B19-VP1u and its sPLA2 enzymatic activity in B19 infection and B19-related diseases.
Background
Human parvovirus B19 (B19) is a human-pathogenic par-
vovirus consisting of a small non-enveloped particle with
a single-stranded linear 5.6-kb DNA genome [1,2]. The
icosahedral capsid consists of two structural proteins, VP1
(83 kDa) and VP2 (58 kDa), which are identical with the
exception of 227 amino acids at the amino-terminal end
of the VP1-protein, the so-called VP1-unique region
(VP1u) [3]. Although VP2 proteins predominate in the
capsid of B19, VP1 is critical in eliciting an appropriate
immune response in both human and animal [4-6]. Pre-
vious studies have shown that antiserum produced by
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immunizing rabbits with a fusion protein containing the
entire unique region sequence of VP1 neutralized the
binding activity of B19 [7]. Recently, a phospholipase A2
(PLA2) motif has been linked to the B19-VP1u [8-11] and
mutation of B19-VP1u in the phospholipase domain
causes a complete loss in enzymatic activity and viral
infectivity (ex: D175A) [10-12]. Although parvovirus
PLA2 has been classified as a group XIII PLA2 [10,13], the
precise function of secreted phospholipases A (sPLA2)
from B19-VP1u is still obscure.
Macrophages are part of the innate immune system and
are derived from monocytes, which develop in the bone
marrow and play important roles in providing the first
line of host defense [14]. The migration of macrophages
through peripheral tissues is an essential step in the host
response to infection and inflammation [15,16]. Addi-
tionally, pro-inflammatory cytokines are important medi-
ators in the inflammatory process and are associated with
the activation of macrophages, which leads to altered
morphology and functional activity [15-17]. Although
various cytokines are elevated in serum from patients with
B19 infection and have been associated with the regula-
tion of macrophages [17-19], the role of B19 VP1u on
induction of cytokines in macrophages is still obscure.
Activity of sPLA2 has been implicated in a wide range of
cellular responses, including cell proliferation, signal
transduction, host defense, and chemokinesis [20-22],
which includes extracellular matrix (ECM) remodeling
[23-26], production of ECM proteins, and the activity of
ECM homeostatic enzymes such as matrix metalloprotei-
nase (MMP) and tissue inhibitor of metalloproteinase
(TIMP). Previous studies have reported that PLA2 pro-
motes dramatic migration and ECM invasion by NIH3T3,
mouse fibrosarcoma, and sarcoma cells, via its high affin-
ity receptor [22], which induces cell migration and MMP-
2 activation via phosphoinositide 3-kinase (PI3K) and Akt
[24,25]. These results indicate an association between
sPLA2 and MMP activation. In our current study, we eval-
uated the enzymatic activity of recombinant B19-VP1u
with PLA2 motif proteins and its effect on macrophages.
Methods
Preparation of recombinant wild type and mutated human 
B19 VP1 unique proteins
E. coli (BL21-DE3) clones containing VP1u or
VP1uD175A cDNA (D175A proteins encoded by genes
with point mutations in the enzyme catalytic site) in pET-
32a expression vector (Novagene, Cambridge, MA) were
obtained as described in our previous work that were used
to produce the rabbit anti-B19-VP1u antibody [27-29].
sPLA2 activity
B19-VP1u and B19-VP1uD175A proteins were assayed for
sPLA2 activity by use of a colorimetric assay (sPLA2 Activ-
ity Kit; Cayman Chemical), in accordance with the manu-
facturer's instruction. Results are expressed as micromoles
per minute per milliliter. Additionally, the incubation of
B19-VP1u or B19-VP1uD175A proteins with rabbit anti-
B19-VP1u, anti-B19-NS1 or normal rabbit IgG [27-29]
was also assayed for sPLA2 activity.
Cell culture
Mouse macrophages RAW 264.7 cells (RAW 264.7) were
originally obtained from American type culture collection
(ATCC) (Manassas, Va, USA) and were cultured in Dul-
becco's modified Eagle medium (DMEM) supplemented
with 10% (v/v) fetal bovine serum at 37°C and 5% CO2
incubator. Inhibitors of MAPK signal pathway were used
to verify the expression ERK1/2 or JNK protein in RAW
264.7 cells. RAW 264.7 cells were incubated with 400 ng
of B19-VP1u recombinant protein in the absence or pres-
ence of 10 M U0126, a ERK inhibitor, or 25 M
SP600125, a JNK inhibitor, (SABiosciences, Co. MD.
USA), for 24 h at 37°C, 5% CO2. The cell lysate were then
obtained and stored at -80°C for further use.
Migration assay
To determine the effect of VP1u or VP1uD175A on cell
motility, cells were seeded into a Boyden chamber (Neuro
Probe, Cabin John, MD) on membrane filters, and migra-
tion of cells stimulated or un-stimulated with VP1u,
VP1uD175A, or VP1u+U0126 was measured as described.
The sPLA2 from bee venom (bvPLA2; Sigma-Aldrich) was
used as a positive control. A modified Boyden chamber
assay using cell culture inserts with a 8-mm pore size poly-
carbonate filter in a 48-well format was used to perform
an in vitro migration assay. Cells were seeded on the
upper part of the chamber at a density of 2 × 105 cells/well
in 50 uL of serum free medium and then incubated for 16
h at 37°C. The bottom chamber contained standard
medium with 10% FBS. The cells that had invaded to the
lower surface of the membrane were fixed with methanol,
washed with dd-H2O, and then stained with Giemsa
(Sigma). Ten random fields were counted for each experi-
ment under a light microscope.
Assessment of phagocytosis
For phagocytosis of Latex beads, 2 × 105 of RAW264.7
cells were cultured in each well of a 16-well Lab-Tek®II
Chamber Slide™ (Nunc, Denmark) overnight and then
stimulated with 400 ng of VP1u or VP1uD175A recom-
binant proteins for 16 h before incubation with FITC-
labelled Latex beads (Sigma, Saint Louis Mo, USA). 100×
FITC-labelled Latex beads were suspended in phosphate
buffered saline (PBS) and opsonized by incubation with
RAW264.7 cells for 4 h at 37°C. One hundred macro-Journal of Biomedical Science 2009, 16:13 http://www.jbiomedsci.com/content/16/1/13
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phages in five random fields were counted by observation
under a light microscope, ZEISS AXioskop2 at a magnifi-
cation of 200×. The phagocytic index was expressed as the
number of phagocytosed particles divided by the total
number of macrophages and expressed as a percentage
[30].
Messenger RNA isolation and RT-PCR
All studies were carried out in a designated PCR-clean
area. After treatments at 0–24 h, washed in Dulbecco's
phosphate buffered saline (DPBS) twice and treated with
Trizol buffer for total RNA extraction. The cDNAs encod-
ing mouse IL-1, IL-6, TNF, and GAPDH were amplified
according to our previous condition [31] and the specific
RNA level of every sample was expressed as the product's
intensity. cDNA encoding glyceraldehyde- 3-phosphate
dehydrogenase (GAPDH) was amplified and quantified
for each sample.
Gel zymography
RAW 264.7 cells were stimulated with VP1u/VP1uD175A
recombinant proteins and the activities of MMP-2 and
MMP-9 in medium were measured by gelatin-zymogra-
phy assays as previously described [32]. Ten microliters of
ten-fold diluted serum or 20 l supernatant were sepa-
rated by an 8% sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) gels containing 0.1% gel-
atin. Gels were washed for 30 min in 2.5% Triton X-100
to remove the SDS and then soaked in the reaction buffer
containing 40 mM Tris-HCl, pH8.0, 10 mM CaCl2 and
0.02% NaN3 for 30 min. Gelatinolytic activity was visual-
ized by staining the gels with 0.5% Coomassie brillant
blue R-250, de-stained with methanol-acetic acid water,
and relative MMP levels were quantitated by a gel docu-
mentation and analysis system (AlphaImager, 2000,
Alpha Innotech Corporation).
Immunoblotting
Protein samples were separated in 12.5 or 10% of SDS-
PAGE and electrophoretically transferred to nitrocellulose
membrane (Amersham Biosciences, Piscataway, NJ, USA)
according to the method of Towbin [33]. After blocking
with 5% non-fat dry milk in (PBS), antibodies against
AKT-p, Erk1/2-p, p38-p, JNK-p and NF-B (p65-p), and
actin (Upstates, Charlottesville, Virginia, USA) were
diluted in PBS with 2.5% BSA and incubated for 1.5 hr
with gentle agitation at room temperature. The mem-
branes were then incubated with horseradish peroxidase
(HRP) conjugated secondary antibody. Pierce's Supersig-
nal West Dura HRP Detection Kit (Pierce Biotechnology
Inc., Rockford, IL) was used to detect the antigen-antibody
complexes. The blots were scanned and quantified by
densitometry (Appraise, Beckman-Coulter, Brea, Califor-
nia, USA).
Statistical analyses
The paired t test and one-way ANOVA were used to ana-
lyze for statistical significance. A P value < 0.05 was con-
sidered significant.
Results
Recombinant B19-VP1u proteins reveal sPLA2 activity
Recent studies have demonstrated that B19-VP1u pos-
sesses phospholipase A2 (PLA2) activity that is postulated
to be involved in a variety of inflammatory reactions [8-
11]. To confirm whether B19-VP1u protein has the PLA2
activity, the recombinant B19-VP1u protein and B19-
VP1uD175A protein, a mutant form of B19-VP1u losing
the PLA2 activity, were purified and analyzed for sPLA2
activity. Table 1 revealed the result of sPLA2 activity. No
sPLA2 activity was detected in B19-VP1uD175A as previ-
ously shown [11]. Notably, apparent sPLA2 activity was
detected in the recombinant B19-VP1u protein with an
activity of 0.19 ± 0.03 mol/min/mL, as well as bvPLA2
which is considered as a positive control with an activity
of 0.56 ± 0.12 mol/min/mL. As expected, significantly
reduced sPLA2 activity was observed in recombinant B19-
VP1u protein that was co-incubated with 5 ug of purified
rabbit anti-B19-VP1u IgG antibodies.
B19-VP1u induces migration and phagocytosis
To test the effect of B19-VP1u on migration of macro-
phages, migration assays were performed as described in
materials and methods. Figure 1A shows the results of
migrated RAW264.7 cells through the membrane pores.
No significant increase in migrated cells was detected in
the VP1uD175A or bvPLA2 groups as compared to the
control group. Notably, a significant increase of migrated
macrophages was observed in the experimental group that
was treated with B19-VP1u proteins as compared to the
control group. In contrast, significantly decreased num-
bers of migrated macrophages were observed in the exper-
imental group that was treated with B19-VP1uD175A or
the B19-VP1u +U0126 as compared to the B19-VP1u
group. To further examine the effect of B19-VP1u on
phagocytosis, RAW264.7 cells were incubated under vari-
ous treatments and co-cultured with FITC-labeled beads.
The phagocytic ability was determined by calculating the
phagocytic index (Figure 1B). Significant increases in the
phagocytic index were detected in the B19-VP1u, B19-
VP1uD175A, bvPLA2, and B19-VP1u+U0126 groups as
compared to the control group. However, a significantly
lower phagocytic index was detected in the B19-
VP1uD175A and the B19-VP1u with U10126 groups as
compared to the B19-VP1u group, respectively (Figure
1B).Journal of Biomedical Science 2009, 16:13 http://www.jbiomedsci.com/content/16/1/13
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B19-VP1u induces IL-6, IL-1 mRNA expression and MMP9 
activity
To examine the effect of B19-VP1u on expression of
inflammatory cytokines in RAW264.7 cells, RT-PCR was
performed. Figure 2A represents the RT-PCR results of IL-
6 and IL-1. Significant increases in IL-6 and IL-1 mRNA
expression were observed in RAW264.7 cells that were
stimulated with B19-VP1u at 12 and 24 h. In contrast, no
induction of IL-6 and IL-1 mRNA expression was
detected in cells that were stimulated with either B19-
VP1uD175A or bvPLA2. Quantified results of IL-6 and IL-
1 levels are shown in the lower panel of Figure 2A. To
examine whether B19-VP1u and its sPLA2 enzymatic
activity could influence the activities of the ECM degrad-
ing proteases such as MMP9 or MMP2, the effect of B19-
VP1u on the secretion of MMPs was investigated using a
zymography assay. As shown in Figure 2B, significant
increases in MMP9 activity was observed at 8, 12 and 24 h
in the experimental group treated with B19-VP1u proteins
as compared to the control group. However, significant
decreases in MMP9 activity were observed in the experi-
mental group that was treated with B19-VP1uD175A at 8,
12 and 24 h as compared to the B19-VP1u group. Quan-
tified results are shown in the lower panel of Fig 2B.
B19-VP1u increases the phosphorylation of ERK 1/2 and 
JNK
To clarify the possible signaling pathways involved in the
activation of macrophages by B19-VP1u, various signaling
molecules including AKT-p, Erk1/2-p, p38-p, JNK-p and
NF-B (p65 -p) were examined. Notably, the phosphor-
ylation of ERK 1/2 and JNK proteins was significantly
increased in RAW264.7 cells that were stimulated with
B19-VP1u as compared to those stimulated with B19-
VP1uD175A or control (Figure 3A and 3B). Additionally,
significant decreases of phosphorylated ERK 1/2 and JNK
proteins were observed in the presence of U0126, an ERK
inhibitor, or SP600125, a JNK inhibitor (Figure 3A and
3B). However, no significant variations of AKT-p, p38-p,
and NF-B (p65-p), were observed in all experimental
groups (data not shown). Quantified results are shown in
the lower panels of Fig 3A and 3B.
Discussion
Human parvovirus B19-VP1u is known to have a phos-
pholipase A2 (PLA2) motif [8-12] and its enzyme activity
has been associated with various inflammatory processes
that may contribute to the activation of macrophages.
However, little is known about the effects of B19-VP1u on
Table 1: Secreted phospholipase A2 (sPLA2) activity of recombinant wild-type or mutated VP1-unique region (VP1u) proteins
Proteins sPLA2 activity
(mol/min/mL)
bvPLA2 (1 ng) 0.56 ± 0.12
VP1u (0.5 ug) 0.03 ± 0.02
VP1u (5 ug) 0.19 ± 0.03 *,&
VP1uD175A(0.5 ug) ND
VP1uD175A (5 ug) ND
Rabbit anti-VP1u IgG (0.5 ug) ND
Rabbit anti-VP1u IgG (5 ug) ND
Rabbit anti-VP1uD175A IgG (0.5 ug) ND
Rabbit anti-VP1uD175A IgG (5 ug) ND
Rabbit IgG (0.5 ug) ND
Rabbit IgG (5 ug) ND
Rabbit anti-NS1 IgG (0.5 ug) ND
Rabbit anti-NS1 IgG (5 ug) ND
VP1u (5 ug) + Rabbit IgG (0.5 ug) 0.18 ± 0.07
VP1u (5 ug) + Rabbit IgG (5 ug) 0.19 ± 0.06
VP1u (5 ug) + Rabbit anti-B19-VP1u IgG (0.5 ug) 0.20 ± 0.11
VP1u (5 ug) + Rabbit anti-B19-VP1u IgG (5 ug) 0.09 ± 0.03 #
VP1u (5 ug) + Rabbit anti-B19-VP1uD175A IgG (0.5 ug) 0.18 ± 0.05
VP1u (5 ug) + Rabbit anti-B19-VP1uD175A IgG (5 ug) 0.16 ± 0.06
VP1u (5 ug) + Rabbit anti-B19-NS1 IgG (5 ug) 0.16 ± 0.04
VP1uD175A (5 ug) + Rabbit anti-B19-VP1u IgG (5 ug) ND
VP1uD175A (5 ug) + Rabbit anti-B19-VP1uD175A IgG (5 ug) ND
bvPLA2: sPLA2 from bee venom; D175A proteins encoded by genes with point mutations in the enzyme catalytic site
ND means non-detected
* and &indicate P < 0.05, compared to VP1u (0.5 ug) or VP1uD175A (5 ug), respectively.
# indicates P < 0.05, compared to VP1u (5 ug).Journal of Biomedical Science 2009, 16:13 http://www.jbiomedsci.com/content/16/1/13
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Migration and phagocytosis of mouse Raw264.7 cells. The cells were incubated with different treatments in the upper compart- ment of Boyden chamber for 16 h Figure 1
Migration and phagocytosis of mouse Raw264.7 cells. The cells were incubated with different treatments in the 
upper compartment of Boyden chamber for 16 h. (A) The migration of cells was determined by counting the number of 
migrated cells in 10 random fields of each well. (B) Phagocytic index of Raw264.7 cells was determined by pre-incubated with 
different preparations for 6 h before addition of FITC-labeled Latex beads. The cells with phogocytic FITC-labeled Latex beads 
were counted in 10 random fields. Similar results were obtained in three independent experiments. I1 indicates U0126. ** and 
## indicate significant differences as compared to the control or the B19-VP1u group, respectively.
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Messenger RNA expression of various cytokines and MMP enzymatic activity in RAW264.7 cells Figure 2
Messenger RNA expression of various cytokines and MMP enzymatic activity in RAW264.7 cells. (A) A repre-
sentative agarose gel of RT-PCR for IL-6, IL-1, and TNF-. GAPDH is used as internal control. The lower panels are the 
quantitated results of IL-6 and IL-1 mRNA. (B) The activities of MMP9 and MMP2 were detected by zymographic assays and 
the quantified results are shown in the lower panels. Similar results were obtained in three independent experiments. C, U, D, 
B indicates experimental groups of control, B19-VP1u, B19VP1uD175A, and bvPLA2. ** and ## indicate significant differences 
as compared to the control or the VP1u group, respectively.
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Increased phosphorylation of ERK1/2 and JNK proteins in RAW264.7 cells pre-incubated with B19-VP1u Figure 3
Increased phosphorylation of ERK1/2 and JNK proteins in RAW264.7 cells pre-incubated with B19-VP1u. The 
representative immunoblotting results for (A) ERK1/2 and (B) JNK proteins hybridized with mouse antibodies against phospho-
rylated -ERK1/2 and -JNK. The quantified results are shown in the lower panel. Similar results were obtained in three inde-
pendent experiments. C, U, D, I1, and I2 indicate the experimental groups of control, B19-VP1u, B19VP1uD175A, U0126, and 
SP600125. ** and ## indicate significant differences as compared to the control or the VP1u group, respectively.
p-ERK 1/2
ERK 1/2
p-JNK
JNK
CU D U + I 1 CUDU + I 1
0 h 24 h
A
B
0h
CU D U + I 2 CU D U + I 2
0 h 24 h
˃
˃ˁ˃ˈ
˃ˁ˄
˃ˁ˄ˈ
˃ˁ˅
˃ˁ˅ˈ
˃
˃ˁ˄
˃ˁ˅
˃ˁˆ
˃ˁˇ
˃ˁˈ
˃ˁˉ
˃ˁˊ
**
##
˃
˃ˁ˃ˈ
˃ˁ˄
˃ˁ˄ˈ
˃ˁ˅
˃ˁ˅ˈ
˃
˃ˁ˄
˃ˁ˅
˃ˁˆ
˃ˁˇ
˃ˁˈ
˃ˁˉ
˃ˁˊ
##
**
##
##
R
a
t
i
o
(
p
-
E
R
K
1
/
2
/
E
R
K
/
1
2
)
R
a
t
i
o
(
p
-
E
R
K
1
/
2
/
E
R
K
1
/
2
)
CUD U + I 1 CU D U + I 1
24 h
R
a
t
i
o
(
p
-
J
N
K
/
J
N
K
)
R
a
t
i
o
(
p
-
J
N
K
/
J
N
K
)
0h
CUD U + I 2 CUD U + I 2
24 hJournal of Biomedical Science 2009, 16:13 http://www.jbiomedsci.com/content/16/1/13
Page 8 of 9
(page number not for citation purposes)
macrophage activation. This is the first study to demon-
strate the role of B19-VP1u and its sPLA2 enzymatic activ-
ity on the induction of macrophage responses that may
contribute to inflammatory processes or diseases. Our
results reveal the sPLA2 activity of recombinant B19-VP1u
proteins can activate macrophages by significantly
increasing migration and phagocytosis. Additionally, sig-
nificant increases of MMP9 activity, IL-6 and IL-1b mRNA
expression were detected in macrophages that were stim-
ulated with B19-VP1u as well as the increased phosphor-
ylation of ERK1/2 and JNK proteins.
Activity of sPLA2 has been implicated in a variety of phys-
iological and pathological responses, including cell prolif-
eration, chemokinesis [20-22], ECM remodeling [23-
26,34], vascular inflammation, [35,36] and cerebral
ischemia [37]. Recently, parvovirus B19-VP1u has been
linked with sPLA2-like activity that is recognized as group
XIII enzyme [10,13], a novel type of sPLA2 that may con-
tribute to various pathological processes [8,26,35-38].
Additionally, a B19-VP1u mutant, B19-VP1uD175A, is
mutated in the phospholipase domain and loses its enzy-
matic activity and viral infectivity [8-13]. However, little is
known about the sPLA2 enzymatic activity of B19-VP1u in
migration and phogocytosis of macrophages that is asso-
ciated with a variety of inflammatory and immune
responses. Notably, our experimental results reveal signif-
icant increases in migration and phagocytosis in
RAW264.7 macrophage cells treated with recombinant
B19-VP1u proteins as compared to the control group. In
contrast, no induction of migration and phagocytosis was
observed in the experimental group that was treated with
B19-VP1uD175A. These experimental results strongly
suggest that the sPLA2 enzymatic activity of B19-VP1u is
crucial to activation of migration and phagocytosis of
macrophages.
Indeed, phospholipase A2 is known to play important
roles in many inflammatory processes and immune
responses including atherosclerosis, pro-inflammatory
cytokine expression, and cerebral ischemia [35,36].
Recent studies have demonstrated the association
between extracellular-matrix-related proteins and inflam-
matory responses via activation of mitogen activated
kinases (MAPKs). In a cerebral-ischemic animal model,
ischemia and organ culture were demonstrated to induce
the activation of p38, ERK 1/2 and SAPK/JNK in cerebral
arteries and the expression of inflammatory and MMP9
genes in the wall of cerebral arteries [24,25,34,35,37].
Additionally, increased secretion of CXCL8 by sPLA(2)-IB
is related to activation of NF-kB in human neutrophils
[38] Recently, various studies have postulated MMP9 may
contribute to the development or pathogenesis of autoim-
munity [39]. However, the roles of B19-VP1u and its
sPLA2 enzymatic activity on B19-related diseases have not
been investigated. Notably, a similar phenomenon was
observed in our experimental results. We demonstrated an
increase in MMP-9 activity, IL-6 and IL-1 mRNA expres-
sion, and phosphorylation of ERK1/2 and JNK proteins in
RAW264.7 cells that were treated with recombinant B19-
VP1u proteins. In contrast, no inductive effects on inflam-
matory related responses were observed in RAW264.7
cells treated with mutant B19-VP1uD175A protein or
B19-VP1u with inhibitors. These experimental results
strongly indicate the importance of sPLA2 activity of B19-
VP1u in activation of macrophages and suggest the
involvement of B19-VP1u and its PLA2 activity in inflam-
matory processes via activation of ERK1/2 and JNK signal-
ing pathways in macrophages.
Conclusion
Taken together, parvovirus B19-VP1u and its sPLA2 enzy-
matic activity are critical for eliciting macrophage
responses associated with a variety of inflammatory proc-
esses. Our experimental results demonstrate the effects of
sPLA2 activity in B19-VP1u proteins by increasing migra-
tion, phagocytosis, and inflammatory responses such as
significant increases of MMP9 activity, IL-6 and IL-1
mRNA expression in macrophages. This study strongly
suggests the crucial role of sPLA2 activity of B19-VP1u in
macrophage activation and may provide clues in under-
standing the role of B19-VP1u in the host response to B19
infection and B19-related diseases.
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